98%
921
2 minutes
20
Delivery of therapeutic or diagnostic agents to the brain is majorly hindered by the blood-brain barrier (BBB). Recently, many studies have demonstrated local and transient disruption of the BBB using low power ultrasound sonication combined with intravascular microbubbles. However, BBB opening and closure mechanisms are poorly understood, especially the maximum gap that may be safely generated between endothelial cells and the duration of opening of the BBB. Here, we studied BBB opening and closure under magnetic resonance (MR) guidance in a rat model. First, MR contrast agents (CA) of different hydrodynamic diameters (1 to 65 nm) were employed to estimate the largest molecular size permissible across the cerebral tissues. Second, to estimate the duration of the BBB opening, the CA were injected at various times post-BBB disruption (12 minutes to 24 hours). A T(1) mapping strategy was developed to assess CA concentration at the ultrasound (US) focal point. Based on our experimental data and BBB closure modeling, a calibration curve was obtained to compute the half closure time as a function of CA hydrodynamic diameter. These findings and the model provide an invaluable basis for optimal design and delivery of nanoparticles to the brain.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463875 | PMC |
http://dx.doi.org/10.1038/jcbfm.2012.100 | DOI Listing |
Ultrason Sonochem
August 2025
Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, Orsay 91401, France. Electronic address:
Microbubble-mediated focused ultrasound is a promising strategy for transient and localized blood-brain barrier (BBB) permeabilization, enabling drug delivery to the brain. Optimizing microbubble stability and acoustic response is essential to maximize treatment efficiency and minimize potential damage. This study introduces an innovative microbubble formulation with a phospholipid-fluoropolymer shell (LIP-POL), designed to enhance circulation persistence while maintaining a low cavitation threshold.
View Article and Find Full Text PDFACS Chem Neurosci
September 2025
College of Pharmacy, Gachon Institute of Pharmaceutical Science, Gachon University, Incheon 21912, Republic of Korea.
Neurological disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis pose significant challenges for treatment. Reasons for the difficulty in finding cures for these conditions include complications in early diagnosis, progressive and irreversible neuronal damage, and the presence of the blood-brain barrier (BBB), which hinders the delivery of drugs to the affected areas of the brain. Intranasal (INL) drug administration has increasingly gained popularity among researchers for targeting neurological conditions, because of its ability to bypass the BBB.
View Article and Find Full Text PDFJ Control Release
September 2025
Research Department of Imaging Chemistry and Biology, School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom. Electronic address:
The blood-brain barrier (BBB) significantly hinders the treatment of central nervous system (CNS) disorders and brain tumors with intact BBB by restricting the entry of most therapeutic agents, including small-molecule drugs and particularly larger macromolecules. Liposomal formulations, such as PEGylated liposomes with long blood half-lives, high drug-carrying capacity, and reduced off-site toxicity, can be useful for brain drug delivery, but their large size often limits BBB penetration. A novel liposomal doxorubicin formulation(Talidox®) with a smaller size (~36 nm, determined by TEM), increased blood circulation half-life (median reported half-life 96 h), and better stability than previous clinical formulations, can be a suitable choice for brain delivery.
View Article and Find Full Text PDFRadiology
September 2025
Department of Diagnostic Radiology and Nuclear Medicine, School of Medicine, University of Maryland, 670 W Baltimore St, Baltimore, MD 21201.
Background Given the current lack of widely adopted strategies for facilitating drug penetration into the brain, developing new techniques to increase blood-brain barrier (BBB) permeability is essential to address the increasing burden of central nervous system disorders. Osmotic blood-brain barrier opening (OBBBO), achieved through intra-arterial delivery of 25% mannitol to the cerebral vasculature, is a pioneering strategy demonstrating both safety and partial efficacy. Purpose To investigate the potential of 25% mannitol with 4% NaCl, a combination that doubles the osmotic power, to safely increase OBBBO efficacy.
View Article and Find Full Text PDFCell Death Discov
August 2025
Department of Human Anatomy, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
Cancer-testicular antigens (CTAs) have been considered as potential prognostic biomarkers and therapeutic targets due to their specific expression and roles in tumorigenesis and metastasis. Among these, the function and mechanism of SPANXB1 in breast cancer brain metastasis (BCBM) remain poorly understood. In this study, we investigated the role of SPANXB1 in BCBM.
View Article and Find Full Text PDF